Kornimate/medical-research-clean huggingface dataset:
response to tregs in innate immunity receptor lrp1 (cd91) and tregs in periferic blood mononuclear cells in patients with non-segmentary vitiligo

Conditions: VITILIGO

Summary: this study aims to evaluate some differences in the immune system between patients with vitiligo and patients without the disease. these differences will be evaluated by the extraction of peripheral blood that will be analyzed before the treatment and after the treatment that, in the habitual way and at the discretion of the responsible dermatologist. patients agreeing to participate in the study will be subjected to extraction of two tubes (20 ml) of peripheral blood (baseline) and after 12 weeks (+/- 5 days) of treatment. therefore, neither treatment nor follow-up visits will be modified by participation, but will be the same whether or not participate in the study. in the case of controls, two peripheral blood tubes (20ml) will be removed in a single participation. patients with vitiligo will also be asked to complete questionnaires to measure stress, depression and perception of disease (pss-10, skindex-29, hads, likert) before and after 12 weeks (+/- 5 days) of therapeutic intervention . this study will include 20 patients with active non-segmental vitiligo and 10 controls without the disease. the duration of participation in this study will be 12 weeks (+/- 5 days) for patients with vitiligo and a single participation (extraction of 20 ml of peripheral venous blood) for the controls.


Eligibility criteria:
inclusion criteria: - patient with vitiligo without treatment exclusion criteria: * patient with inmunosupressive disease * patient receiving vitiligo treatment

Keywords: tregs cd91 lrp1
testosterone replacement therapy in chronic spinal cord injury

Conditions: Spinal Cord Injury; Hypogonadism

Summary: it has long been recognized that co-morbidity associated with multiple metabolic syndrome, such as adverse body composition, insulin resistance and autonomic nervous system impairment, may lead to significant increase in cardiovascular morbidity and mortality. it is unclear whether the co-morbidity evident in this population are due directly to their immobility or are the result of unfavorable changes in their underlying hormonal milieu. the purpose of this study is to determine the effect of testosterone replacement therapy in hypogonadal males on: body composition, i.e. lean tissue and fat mass, glucose tolerance, resting energy expenditure, autonomic-cardiovascular integrity, muscular strength, psychological assessment

this study is 24 months in duration. men who have consented to pre-screening serum testosterone draw and are found to have total testosterone levels averaging ≤ 11.3 nmol/l will start testosterone replacement therapy after a 6-month baseline period. once treatment begins subjects will place a testosterone replacement patch (5 or 10 mg/day) on various sites of the body daily. subjects will visit the lab after 2,6, 12, and 18 months of therapy for testing; however they will stop taking the patch at the 12 month visit. if needed, a steroid cream will be provided to the subjects should any skin irritations occur. if the patch causes persistent skin irritations, despite use of the steroid cream, then a testosterone gel may be used. detailed instructions and precautions using the gel are outlined in the consent form and will be reviewed with the subject. those men who have consented to pre-screening serum testosterone and are found to have normal levels of total testosterone (testosterone total ≥ 11.4 nmol/l) are eligible to participate as a control subject for the full 24-month period of the study. these subjects visit the lab at baseline (bl), 12 and 24 months for the same testing as those in the treatment group.

Eligibility criteria:
inclusion criteria: * males 18-49 years of age * chronic spinal cord injury * normal prostate specific antigen levels and digital rectal exam * no known cardiovascular disease * subjects with total testosterone \> 4 ng/ml * subjects with total testosterone \> 4 ng/ml exclusion criteria: * females * known coronary heart and/or artery disease, diabetes mellitus * previous or current cancer * current or previous anabolic steroid use * acute inter-current illness * abnormal liver function test (\>1.5 times normal values) at baseline * prostate specific antigen above normal * abnormal digital rectal exam at baseline suggestive of malignancy * current alcohol or drug abuse * significant psychological disorders

Keywords: spinal cord injury testosterone replacement therapy dual energy x ray absorptiometry lean tissue mass
aortic cross-clamping and systemic inflammatory response in humans: effect of ischemic preconditioning

Conditions: Aortic Aneurysm

Summary: multiple organ dysfunction syndrome is a major cause of morbidity and mortality after abdominal aortic aneurysm (aaa) surgery. it is postulated that aortic cross-clamping during open aaa repair may cause ischemia-reperfusion (i/r) leading to the systemic releases of reactive oxygen species (ros) and inflammatory cytokines which damage distant organs, including heart, kidney, and lung. ischemic preconditioning, first described in cardiac surgery, is a mechanism whereby tissues exposed to a brief period of nonlethal i/r develop resistance to subsequent ischemic insult. remote ischemic preconditioning (ripc), is a phenomenon whereby brief periods of ischemia followed by reperfusion in one organ (usually skeletal muscle) provide systemic protection from prolonged ischemia. the mechanisms through which ripc confer organ protection remains unclear. the hypothesis is that limb ripc would reduce systemic inflammatory mediators produced by ischemia-reperfusion and thereby protect the remote organs. a single-center, prospective, randomized, parallel-group controlled trial is conducted on patients undergoing elective open infrarenal aaa repair. written informed consent is obtained from each participant. the study protocol was reviewed and approved by the research ethics committee of rouen, france. patients are divided in two groups : the sham-operated control group underwent surgery without ripc and the ripc group : two cycles of intermittent crossclamping of the common iliac artery (right or left) with 10 minutes ischemia followed by 10 minutes reperfusion served as the ripc stimulus, before prolonged ischemia. blood samples are collected for analysis at the following time points: before surgery (baseline), 1, 3 and 24 h after cross-clamp release (reperfusion). the systemic inflammatory response is measured using the serum concentrations of tnf-alpha, and il 1, 4, 6, 10. cardiac, renal and pulmonary functions are evaluated with usual biological markers and clinical monitoring until 28 days after surgery. aortic surgery is a perfect clinical model of ischemia-reperfusion which makes it possible to study the impact of ripc in humans. this biological approach would help to better understand the mechanisms underlying this technique.


Eligibility criteria:
inclusion criteria: * patients undergoing elective open infrarenal abdominal aortic aneurysm repair * scheduled surgery * patients aged 30-85 years old exclusion criteria: * patients undergoing endovascular treatment for infrarenal abdominal aortic aneurysm * patients younger than 30 years and older than 85 years * pregnant women or nursing mother * adult under guardianship * refusal to sign a consent * patients whose survival at 28 days is unlikely * surgery requiring subphrenic aortic cross-clamping * emergency surgery * patients taking sulfonylureas or nicorandil * patients having contraindication to clamp iliac arteries * dementia
effect of lactobacillus reuteri dsm17938 in neonates treated with antibiotics

Conditions: Gastrointestinal Diseases; Colic

Summary: the aim of the study is to elucidate the relationship between postnatal antibiotic administration on development of gut microbiota and possible protective influence of simultaneously administration of probiotic during antibiotic therapy on development of gut microbiota, functional gastrointestinal disorders of infancy, weight gain and body composition.

the study is double-blind, placebo-controlled randomised trial and is composed from two parts. first part of the study aims to examine any difference in gut microbiota after postnatal antibiotic administration between the neonates who received probiotic lactobacillus reuteri dsm 17938 or placebo and to compare the gut microbiota of patients to microbiota of healthy newborns. second part of the study aims to determine whether probiotic l. reuteri dsm 17938 supplementation to antibiotic therapy has any beneficial influence on incidence of functional gastrointestinal disorders of infancy and body composition and bone density 6 weeks and one year after inclusion in the study. additionally the associations of the clinical parameters with the composition and developmental characteristics of fecal microbiota during antibiotic treatment in children will be evaluated; relevant clinical data such as mode of delivery, child's nutrition, health problems, growth and developmental attributes which could be found associated with fecal microbial community, will be tracked and statistically evaluated for the investigated population.

Eligibility criteria:
inclusion criteria: * term neonates whom antibiotic treatment will be introduced due to clinical suspicion of infection exclusion criteria: * gestational age under 37 weeks * birth weight less than 2500 grams * congenital malformations/syndromes * perinatal hypoxia * who had received probiotics before the randomization * have had cow's milk protein allergy diagnosed during the study * patient who will be treated with antibiotic for less than 5 days

Keywords: probiotics anti-bacterial agents infant, newborn gastrointestinal microbiome colic gastrointestinal diseases body composition bone density randomized controlled trial lactobacillus reuteri pediatrics feces ultrasonography high-throughput nucleotide sequencing electric impedance surveys and questionnaires
study of shr-8068 combined with adebrelimab and bevacizumab versus sintilimab combined with bevacizumab for the treatment of advanced hepatocellular carcinoma

Conditions: Advanced Hepatocellular Carcinoma

Summary: to evaluate the efficacy of shr-8068 combined with adebrelimab and bevacizumab compared with sintilimab combined with bevacizumab for the first-line treatment of advanced hcc


Eligibility criteria:
inclusion criteria: 1. able and willing to provide a written informed consent 2. ≥ 18 years old, both male and female 3. unresectable locally advanced or metastatic hcc confirmed by histopathologically/cytologically 4. at least one measurable lesion based on recist v1.1 criteria 5. barcelona clinic liver cancer: stage b or c 6. no previous systemic antitumor therapy for hcc 7. ecog ps of 0-1 8. child-pugh score of a or b7 9. expected survival period ≥ 12 weeks 10. adequate organ function 11. blood pregnancy negative (women of childbearing age) and non-breastfeeding, effective contraception exclusion criteria: 1. hepatic cholangiocarcinoma, mixed hepatocellular carcinoma -cholangiocarcinoma, sarcomatoid hepatocellular carcinoma and fibrolamellar hepatocellular carcinoma 2. patients with other malignancies currently or within the past 5 years 3. with known severe allergic reactions to any other monoclonal antibodies 4. patients with known cns metastasis or hepatic encephalopathy 5. patients with liver tumor burden greater than 50% of total liver in volume or received liver transplants 6. patients with symptomatic ascites or pleural effusion 7. patients with hypertension which cannot be well controlled by antihypertensives 8. uncontrolled cardiac diseases or symptoms 9. known hereditary or acquired bleeding (e.g., coagulopathy) or a tendency to clot (e.g., hemophiliacs) 10. major vascular disease occurred in the 6 months before randomization 11. gastrointestinal perforation or gastrointestinal fistula within 6 months before randomization 12. major surgery within 28 days before randomization or expected to require major surgery during the study period 13. active infection, or fever of unknown cause ≥ 38.5℃ in the first 7 days of randomization, or wbc \> 15×109/l at baseline 14. known positive history of human immunodeficiency virus test or acquired immunodeficiency syndrome, known hbv infection, known hcv infection 15. patients who received live vaccines within 28 days before randomization, or are expected to be vaccinated during the treatment period 16. patients with other potential factors that may affect the study results
impact of dyspnea on patients in the intensive care unit

Conditions: Dyspnea

Summary: although pain has been extensively studied in icu patients, only a few studies have focused on dyspnea, which is experienced by 50% of mechanically ventilated patients. the purpose of the present study is to determine whether dyspnea in intensive care unit patients is associated with a higher length of stay in the icu and a higher incidence of post traumatic stress disorders.

intensive care unit (icu) patients are continuously exposed to various unpleasant sensations that are as many sources of discomfort. if, growing attention has been given to the detection and treatment of pain, very little attention has been given to dyspnea. however, there is growing evidence suggesting that dyspnea is frequent and severe in mechanically ventilated icu patients. in mechanically ventilated icu patients, dyspnea is independently associated with anxiety and mechanical ventilation itself. indeed, an optimization of ventilator settings alleviates dyspnea in 35% of patients. various arguments suggest that dyspnea contributes to the dark experience of icu and participates to the genesis of post traumatic stress disorders. in addition, dyspnea is associated with a longer duration of mechanical ventilation. large multicentre studies are however lacking. the aims of the present multicentre study are 1) to quantify the prevalence of dyspnea in a large population of icu mechanically ventilated patients, 2) to examine the link between the level of dyspnea and the occurrence of adverse events in the icu, 3) to determine whether dyspnea in intensive care unit patients is associated with a higher length of stay in the icu and a higher incidence of post traumatic stress disorder associated symptoms.

Eligibility criteria:
inclusion criteria: * invasive mechanical ventilation in the icu for \> 24 hours * remaining stay in the icu estimated \> 24 hours exclusion criteria : * rass \ +2 * delirium (defined according to cam-icu) * severe cognitive impairment or severe psychiatric disease * patient who does not understand french * severe depthless * age \<18 years
clinical evaluation of the photoallergy potential of xenaderm ointment

Conditions: Healthy

Summary: the product is being tested to see if exposure to light causes photoallergic reactions on the skin.


Eligibility criteria:
inclusion criteria: * healthy subjects exclusion criteria: * less than 18 years

Keywords: wound healing photoallergenicity healthy subjects
use of platelet rich plasma in the management of acute hamstring muscle strain injury

Conditions: Acute Hamstring Muscle Strain Injury

Summary: the purpose of this study is to evaluate the therapeutic benefit of utilizing complex growth factor preparations (platelet rich plasma (prp) in the management of acute hamstring injuries. the hypothesis is that the time to return to sport is shorter in the patient group treated with complex growth factor preparations (prp) in combination with exercise therapy in comparison with 2 control groups: * the patient group treated with platelet poor plasma (ppp) injections in combination with exercise therapy (control injection and usual care). * the patient group treated with exercise therapy (usual care)


Eligibility criteria:
inclusion criteria: * acute onset posterior thigh pain * mri confirmed grade i, ii hamstring lesions * \< 5 days from injury * able to perform physiotherapy at aspetar (5 sessions/week) * available for follow-up * male * age \> 18 years exclusion criteria: * diabetes, immuno-compromised state * overlying skin infection * re-injury or chronic ongoing hamstring injury * unwilling to comply with follow up * contraindication to mri * needle phobia * bleeding disorder or other medical contraindication to injection * medication increasing bleeding risk (e.g. plavix) * concurrent other injury inhibiting rehabilitation

Keywords: platelet rich plasma interventional randomized double-blind
effect of intensive cognitive rehabilitation on cognitive, motor, and language functional networks in subacute stroke patient

Conditions: Stroke

Summary: altered brain networks, including cognitive, motor, and language networks, are investigated by intensive cognitive rehabilitation in subacute stroke patients.


Eligibility criteria:
inclusion criteria: * patients aged 19 to 80 years * patients with subacute stroke within 2 weeks of onset * first-ever stroke * supratentorial stroke * less than 8 safe (shoulder abduction, finger extension) points * less than 35 fma upper scores * mep (motor evoked potential) negative * not more than 24 k-mmse (korean mini-mental state examination) score exclusion criteria: * difficult to communicate due to severe language impairment. * accompanied by an existing serious neurogenic disease * existing significant psychiatric disorders such as major schizophrenia, bipolar disorder * if there are difficulties in conducting the research * any patients who are judged by the investigator to be difficult to participate in this study * patients with contraindicated mri scans
a study of weekly taxotere and xeloda in metastatic breast cancer

Conditions: Metastatic Breast Cancer

Summary: the purpose of this study is to attempt to find better tolerated doses and schedules of this highly effective combination chemotherapy regimen.

combination chemotherapy has advantages over monochemotherapy due to the higher response rates that can often be obtained; by using agents with non-overlapping toxicity profiles, these responses can be achieved with less toxicity than maximally tolerated doses of single agents. one significant advantage of capecitabine/weekly docetaxel combination chemotherapy is that both agents appear to have a toxicity profile appropriate for palliative therapy of advanced breast cancer. this trial will utilize the usual schedule of capecitabine used in the usa, which is two times per day oral dosing for 14 days but at a reduced dose in hopes of decreasing toxicities. docetaxel will be given weekly at a dose of 35 mg/m2 x 2 with a one-week rest to coincide with the 14-day schedule of capecitabine. the primary objective is to evaluate the overall response rate (complete and partial responses) according to the recist criteria of the combination of capecitabine and docetaxel with the selected schedule in patients with advanced and/or metastatic breast cancer. the secondary objectives are to evaluate tolerability, time to tumor progression, and time to treatment failure of the combination of capecitabine and docetaxel.

Eligibility criteria:
inclusion criteria: * female patients with histopathologically proven metastatic breast cancer. * patients 18-75 years old * performance status: karnofsky \> 70% * patients must have measurable disease. patients with only blastic bone lesions are ineligible. * adequate bone marrow, liver, renal and cardiac functions defined as: * ability to understand the study and give informed consent. * patients may not have received more than one prior chemotherapy for metastatic breast cancer. 5-fu or taxol given as part of an adjuvant regimen will not render the patient ineligible. exclusion criteria: * patients with brain metastasis, adequately treated and stable and not requiring continued steroid medication will be eligible if no progression for \> 3 months. * patients who have received any anti-cancer investigational agent in the month prior to inclusion. * patients previously treated with docetaxel(taxotere)or capecitabine (xeloda). * patients with lack of physical integrity of the upper gastrointestinal tract, inability to swallow tablets or those who have malabsorption syndrome. * patients with renal impairment (creatinine clearance below 30 ml/min calculated according to cockcroft and gault, see appendix d), since capecitabine is contraindicated in patients with severe renal impairment.

Keywords: metastatic breast cancer taxotere (docetaxel) xeloda (capecitabine)
atorvastatin as an antihypertensive agent

Conditions: Atorvastatin Antihypertensive Effect

Summary: this study is aimed to see the antihypertensive effect of statin (atorvastatin) as certain animal models have shown that statins have the voltage-gated calcium channel blocking effect. it will be a randomized controlled trial that will be done in ayub hospital complex abbottabad. after ethical approval, 120 patients with newly diagnosed hypertension belonging to either gender and aged 35 and above will be enrolled in the trial. they will randomly be grouped into two groups with each group comprising 60 patients. one group will be administered amlodipine 5 mg po once a day, while the other one will be given 5mg amlodipine plus 10 mg atorvastatin. the patients will be examined on a follow-up visit 14 days later and blood pressure will be recorded as per protocols.


Eligibility criteria:
inclusion criteria: - the inclusion criteria for the study were all newly diagnosed hypertensive patients aged 35 years and above with normal lipid profile exclusion criteria: * patients with a history of dyslipidemias, diabetes mellites, chronic kidney disease, and ischemic heart disease